|
"Mechanisms of Damage-Induced Homologous Recombination"
|
5R01CA079827-08
|
$240,133
|
$240,133
|
SAMSON, LEONA
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
|
"Starve the Tumor Cells to Death": SLC6A14 as a Drug Target for Colon Cancer
|
1R21CA152396-01
|
$191,835
|
$191,835
|
GANAPATHY, VADIVEL
|
MEDICAL COLLEGE OF GEORGIA (MCG)
|
|
(1/2) University of Guam/University of Hawaii Cancer Center Partnership
|
5U54CA143727-09
|
$1,119,110
|
|
PALAFOX, NEAL
|
UNIVERSITY OF HAWAII AT MANOA
|
|
(11) Diet Modification to Augment Radiation for Breast Cancer Brain Metastases
|
1R01CA227479-01
|
$351,726
|
|
SIMONE, NICOLE
|
THOMAS JEFFERSON UNIVERSITY
|
|
(2/2) CDU/UCLA Cancer Center Partnership to Eliminate Cancer Health Disparities
|
5U54CA143930-09
|
$714,423
|
$121,452
|
FARIAS-EISNER, ROBIN
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
(8) Genetics of Immune Related Adverse Events and Response to Immunotherapy
|
1R01CA227466-01
|
$699,062
|
|
ZIV, ELAD
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
(8) Genomic determinants of the T-cell regulome in immune checkpoint blockade
|
1R01CA227505-01
|
$620,860
|
|
KIRCHHOFF, TOMAS
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
(8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitors
|
1R01CA227473-01
|
$580,767
|
|
HEROLD, KEVAN
|
YALE UNIVERSITY
|
|
(9) Biophysical Description of Age and Dose Dependent Changes to Dendritic Morphology that Impact Cognition following Radiation Cancer Therapy
|
5R01CA208526-03
|
$472,047
|
|
CUCINOTTA, FRANCIS
|
UNIVERSITY OF NEVADA LAS VEGAS
|
|
(PQ 12) Targeting SMPDL3b to Prevent Radiation-Induced Nephrotoxicity
|
1R01CA227493-01
|
$427,990
|
|
MARPLES, BRIAN
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
(PQ 9) Synaptic basis of deficits in attention and executive function following cranial radiation
|
5R01CA208535-03
|
$506,533
|
|
GROSSHANS, DAVID
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
(PQ#9) Promoting Axon Stability to Prevent Therapy-induced Peripheral Neuropathy
|
5R01CA219866-02
|
$465,400
|
|
DIANTONIO, AARON
|
WASHINGTON UNIVERSITY
|
|
(PQ1) Epigenetic effects of the premalignant field
|
5R01CA208620-03
|
$415,599
|
|
TERADA, LANCE
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
(PQ1) Molecular circuit of multi-ciliogenesis regulates choroid plexus differentiation and tumor development
|
5R01CA220551-03
|
$315,193
|
|
ZHAO, HAOTIAN
|
NEW YORK INST OF TECHNOLOGY
|
|
(PQ1) Progenitor cell malfunction, mutations and changes in microenvironment: A dynamic risk spectrum for cancer evolution
|
5R01CA219893-02
|
$427,989
|
|
GHOSH, MOUMITA
|
NATIONAL JEWISH HEALTH
|
|
(PQ1) Progression of the airway field of injury to Kras mutant lung cancer
|
5R01CA205608-03
|
$346,909
|
|
SCHEET, PAUL
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
(PQ10) Enhancing responses to immune checkpoint blockade in melanoma via modulation of the microbiome
|
1R01CA219896-01A1
|
$429,943
|
|
WARGO, JENNIFER
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
(PQ10) Harnessing the human gut microbiome to predict chemotherapy outcomes
|
1R21CA227232-01
|
$208,746
|
$208,746
|
TURNBAUGH, PETER
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
(PQ10) The impact of the gut microbiome on the anti-tumor effects of radiotherapy
|
1R01CA219871-01A1
|
$451,326
|
|
FACCIABENE, ANDREA
|
UNIVERSITY OF PENNSYLVANIA
|
|
(PQ10) Understanding How Commensal Microbiota Affect the Anti-tumor Action of Radiotherapy
|
1R21CA227528-01
|
$176,175
|
$176,175
|
WEICHSELBAUM, RALPH
|
UNIVERSITY OF CHICAGO
|
|
(PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer.
|
5R01CA208644-03
|
$377,438
|
$377,438
|
CRITTENDEN, MARKA
|
PROVIDENCE PORTLAND MEDICAL CENTER
|
|
(PQ12) Peroxisome proliferator-activated receptor alpha agonists as potential treatment for chemotherapy-induced peripheral neuropathy
|
1R01CA219637-01A1
|
$281,441
|
|
DAMAJ, M IMAD
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
(PQ3) A functional genomic approach to identification and interpretation of germline-tumor genetic interactions
|
1R01CA227237-01
|
$686,519
|
|
GUSEV, ALEXANDER
|
DANA-FARBER CANCER INST
|
|
(PQ3) Cellular and Molecular Mechanisms Driving Myeloid Compartment Variation in Human Triple Negative Breast Cancer
|
5R01CA219880-02
|
$670,182
|
|
PALUCKA, ANNA KAROLINA
|
JACKSON LABORATORY
|
|
(PQ3) Disruption of immune surveillance by aneuploidy and aberrant MHCII expression
|
5R01CA220009-02
|
$310,000
|
|
ZANETTI, MAURIZIO
|
UNIVERSITY OF CALIFORNIA, SAN DIEGO
|
|
(PQ3) Immune epigenetic biomarkers of bladder cancer outcomes
|
5R01CA216265-02
|
$602,394
|
|
CHRISTENSEN, BROCK
|
DARTMOUTH COLLEGE
|
|
(PQ3) The role of damaged DNA in inter-individual variation of tumor immunity
|
5R01CA208756-03
|
$518,165
|
$518,165
|
HACOHEN, NIR
|
BROAD INSTITUTE, INC.
|
|
(PQ4) Anal HPV infection and anal HSIL among HIV-infected MSM aged 50+ years
|
5R01CA206477-03
|
$791,933
|
|
PALEFSKY, JOEL
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
(PQ5) Exploring the Biological Distinctions between HIV-related and Endemic Pediatric Kaposi Sarcoma in a Kaposi Sarcoma-Associated Herpesvirus-Endemic Region of Africa
|
5R21CA217137-02
|
$196,947
|
|
EL-MALLAWANY, NADER
|
BAYLOR COLLEGE OF MEDICINE
|
|
(PQ5) Imaging mitochondrial heterogeneity in LKB1 mutant lung cancer
|
5R01CA208642-03
|
$352,275
|
|
SHACKELFORD, DAVID
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
(PQ5) Mitochondria in Leukemic Stem Cell Disease Progression
|
5R01CA205975-03
|
$386,619
|
|
GHAFFARI, SAGHI
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
(PQ5) Relevance of VDAC2 heterogeneity for hepatic tumor growth and targeting
|
1R01CA216254-01A1
|
$413,916
|
$413,916
|
HAJNOCZKY, GYORGY
|
THOMAS JEFFERSON UNIVERSITY
|
|
(PQ6) Roles of circadian rhythms in tumor development
|
1R21CA227379-01
|
$208,800
|
$208,800
|
HONG, CHRISTIAN
|
UNIVERSITY OF CINCINNATI
|
|
(PQ6): Is Adrenergic Stress-induced Immune Suppression at the Crossroads of Circadian Rhythm Disruption and Cancer?
|
1R21CA227375-01
|
$224,199
|
|
REPASKY, ELIZABETH
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
(PQ7) Quantitative in vivo optical imaging of tumor heterogeneity
|
5R01CA205101-03
|
$384,612
|
|
SKALA, MELISSA
|
MORGRIDGE INSTITUTE FOR RESEARCH, INC.
|
|
(PQ9) Directed and unbiased studies of synaptic injuries as sequelae of radiotherapy: mapping, sex-dependence, and reversal
|
5R01CA219667-02
|
$523,048
|
|
DUMAN, JOSEPH
|
BAYLOR COLLEGE OF MEDICINE
|
|
(PQ9) A NOVEL MECHANISM OF PACLITAXEL-INDUCED PERIPHERAL NEUROPATHY AND POTENTIAL TREATMENT
|
5R01CA208765-03
|
$343,846
|
|
YANG, QING
|
UNIVERSITY OF TEXAS MED BR GALVESTON
|
|
(PQ9) Characterization and prophylactic treatment of chemotherapy-induced long-term adverse sequelae
|
5R01CA208634-03
|
$560,277
|
|
JURECIC, ROLAND
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
(PQB-1) Telomere maintenance defects and thyroid second cancer in childhood cancer survivors
|
5R01CA194473-04
|
$119,807
|
|
GRAMATGES, MARIA
|
BAYLOR COLLEGE OF MEDICINE
|
|
(PQC3) Ethnicity-determined immune response and DCIS outcome
|
5R01CA194600-04
|
$179,518
|
|
BADVE, SUNIL
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
1/2 Cherokee Nation/Stephenson Cancer Center Collaborative on Cancer Disparities
|
5P20CA202923-04
|
$54,305
|
|
KHAN, SOHAIL
|
CHEROKEE NATION
|
|
1/2 NCCU-DUKE Cancer Disparities Translational Research Partnership
|
5P20CA202924-03
|
$190,920
|
|
WILLIAMS, KEVIN
|
NORTH CAROLINA CENTRAL UNIVERSITY
|
|
1/2 SDSU/UCSD Cancer Center Comprehensive Partnership
|
5U54CA132379-09
|
$1,304,869
|
$587,191
|
MARTINEZ, MARIA
|
UNIVERSITY OF CALIFORNIA, SAN DIEGO
|
|
1/2 The GUIDE Cancer Research Training Project
|
5P20CA202908-04
|
$186,883
|
|
WINN, ROBERT
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
|
1/2 The University of Massachusetts, Boston - Dana-Farber/Harvard Cancer Center U54 Comprehensive Partnership for Cancer Disparities Research
|
5U54CA156734-08
|
$1,691,502
|
$101,490
|
COLON-CARMONA, ADAN
|
UNIVERSITY OF MASSACHUSETTS BOSTON
|
|
1/2-Regional Geohealth Hub Centered in Peru-Peru
|
5U01TW010107-04
|
$224,955
|
|
GONZALES, GUSTAVO
|
UNIVERSIDAD PERUANA CAYETANO HEREDIA
|
|
1/2: Partnership to study racial/ethnic differences in GI cancer biology
|
5P20CA192994-04
|
$277,311
|
$277,311
|
LI, ELLEN
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
|
1/3: The Chicago Collaborative to Promote and Advance Cancer Health Equity
|
5U54CA203000-04
|
$969,219
|
|
SIMON, MELISSA
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
124I-NaI PET: Building block for precision medicine in metastatic thyroid cancer
|
5R01CA201250-03
|
$695,342
|
|
LARSON, STEVEN
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
15-LOX-1 Regulation of Resolving Generation to Modulate Colon Cancer
|
5R01CA195686-03
|
$366,000
|
$366,000
|
SHUREIQI, IMAD
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
Total relevant funding to Digestive Diseases for this search: $641,516,693
|